A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic
In August 2018, a tiny biotech spinout from Cornell announced they had hired former high-ranking Pfizer executive Geno Germano as CEO. And then they said nothing else. For two years. Literally, the company, called Elucida Oncology, did not issue a single other press release until this past October, when they hired a chief medical officer.
Now, though, Elucida seems to be ready to start taking the lid off their operations. On Tuesday at JP Morgan, Germano walked investors through the nanoparticle technology they’ve been developing for cancer. And the same day, the company announced a new financing, raising $44 million in a Series “A-1” round meant to propel them into the clinic this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.